The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity‐Matched Comparison With Standard Perioperative Therapy
Journal of Surgical Oncology · 2025
DOI: 10.1002/jso.27934 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Ahmet Rencuzogullari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, School of Medicine, Koç University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Stomach Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
The FLOT 4‐AIO trial established the docetaxel‐based regimen's superiority over epirubicin‐based triplet therapy in terms of survival rates and acceptable toxicity for locally advanced resectable gastric (LARGC). Yet, fewer than half of the patients achieved completion of eight prescribed FLOT cycles. We proposed that administering all FLOT cycles in the form of total neoadjuvant therapy may improve completion rates and downstaging. This study contrasted total neoadjuvant therapy (FLOT x8) with standard neoadjuvant therapy (FLOT 4+4) for patients LARGC adenocarcinoma who underwent curative resection with routine D2 lymphadenectomy, focusing on histopathological outcomes, toxicity, and survival outcomes.
Methods
We reviewed patients with histologically confirmed advanced clinical stage cT2 or higher, nodal positive stage (cN+), or both, with resectable gastric tumors and no distant metastases (January 2017 to July 2023). We divided patients into two groups, FLOT 4+4 and FLOT x8; FLOT 4+4 patients underwent four preoperative and four postoperative bi‐weekly cycles of docetaxel, oxaliplatin, leucovorin, and fluorouracil, while FLOT x8 patients received all eight cycles preoperatively after a gradual practice change starting from January 2020. Propensity score matching adjusted for age, clinical stage, tumor location, and histology.
Results
Of the 77 patients in the FLOT x8 group, 37 were propensity‐matched to an equal number in the FLOT 4+4 group. Demographics, duration of surgery, and hospital stay showed no significant differences between the groups. The FLOT x8 group exhibited a significantly higher all‐cycle completion rate at 89.1% compared to FLOT 4+4's 67.6% ( p < 0.01). Both groups demonstrated comparable hematological and non‐hematological toxicity rates, Clavien−Dindo ≥ 3 complications, and CAP tumor regression grades. The mean number of harvested lymph nodes was 42.5 and 41.2 in the FLOT 4+4 and FLOT x8 groups, respectively. Similar rates of disease‐free survival and overall survival were noted in both groups, despite a trend toward a higher pathological complete response rate, albeit not statistically significant (8.1% vs. 18.9%, p = 0.29), in the FLOT x8 group at a median follow‐up of 36 months.
Conclusion
Total neoadjuvant therapy with the FLOT x8 protocol corresponds to higher treatment completion rates, a safety profile similar to standard perioperative therapy, and a twofold increase in complete pathological response. Further research on long‐term oncological outcomes is needed to confirm the effectiveness of total neoadjuvant therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, School of Medicine, Koç University, Istanbul, Turkey.
- Department of Medical Oncology, School of Medicine, Koç University, Istanbul, Turkey.
- Department of Pathology, School of Medicine, Koç University, Istanbul, Turkey.
- Department of Radiology, School of Medicine, Koç University, Istanbul, Turkey.
- Department of Medical Oncology, Demiroglu Bilim University, Istanbul, Turkey.
- Department of General Surgery, American Hospital, Istanbul, Turkey.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Rencuzogullari, A., Karahan, S. N., Selcukbiricik, F., Lacin, S., Taskin, O. C., Saka, B., Karahacioglu, D., Gurses, B., Ozoran, E., Uymaz, D. S., Ozata, I. H., Saglam, S., Bugra, D., & Balik, E. (2025). The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity‐Matched Comparison With Standard Perioperative Therapy. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27934
Vancouver
Rencuzogullari A, Karahan SN, Selcukbiricik F, Lacin S, Taskin OC, Saka B, et al. The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity‐Matched Comparison With Standard Perioperative Therapy. Journal of Surgical Oncology. 2025. doi:10.1002/jso.27934
BibTeX
@article{Rencuzogullari2025,
author = {Rencuzogullari, Ahmet and Karahan, Salih Nafiz and Selcukbiricik, Fatih and Lacin, Sahin and Taskin, Orhun Cig and Saka, Burcu and Karahacioglu, Duygu and Gurses, Bengi and Ozoran, Emre and Uymaz, Derya Salim and Ozata, Ibrahim Halil and Saglam, Sezer and Bugra, Dursun and Balik, Emre},
title = {The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity‐Matched Comparison With Standard Perioperative Therapy},
journal = {Journal of Surgical Oncology},
year = {2025},
doi = {10.1002/jso.27934}
}
EUVIMED